Caution for interstitial lung disease as a cause of CA 15-3 rise in advanced breast cancer patients treated with everolimus

MeSH terms

• Antineoplastic Agents / adverse effects*
• Breast Neoplasms / blood*
• Breast Neoplasms / complications*
• Breast Neoplasms / drug therapy
• Drug Monitoring / methods
• Everolimus
• Female
• Humans
• Lung Diseases, Interstitial / blood*
• Lung Diseases, Interstitial / etiology*
• Mucin-1 / blood*
• Mucin-1 / immunology
• Sirolimus / adverse effects
• Sirolimus / analogs & derivatives*
• Treatment Outcome